News >

Atezolizumab Regimen Improves PFS in Frontline Nonsquamous NSCLC

Kristie L. Kahl
Published: Tuesday, Sep 25, 2018

Vassiliki A. Papadimitrakopoulou, MD

Vassiliki A.

Papadimitrakopoulou, MD
The addition of atezolizumab (Tecentriq) to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival (PFS) in patients with stage IV nonsquamous non–small cell lung cancer (NSCLC).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication